Royalty Report: Drugs, Therapeutic, Ophthalmological – Collection: 1039

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Therapeutic
  • Ophthalmological
  • Pharmaceuticals
  • Disease
  • Cancer
  • Diagnostic
  • Biotechnology
  • Diabetes Treatment
  • Medical
  • Device
  • Nutraceutical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1039

License Grant
A federal jury found the Company liable for certain inventions relating to the use of verteporfin (the active pharmaceutical ingredient in Visudyne®) as the photoactive agent in the treatment of certain eye diseases including AMD –  a treatment for the wet form of Age related macular degeneration.

IPSCIO Record ID: 26696

License Grant
The co-owners of  â€˜349 patent entered into an exclusive license with a Hospital for its rights under the ‘349 patent.
License Property
The Patent relates to the use of verteporfin (the active pharmaceutical ingredient in Visudyne®) as the photoactive agent in the treatment of certain eye diseases including AMD (treatment for the wet form of macular degeneration).

IPSCIO Record ID: 26063

License Grant
The Licensor will, among other things, receive exclusive U.S. rights to the Visudyne® patents to sell and market Visudyne in the U.S.  Visudyne, a photosensitizer co-developed with the Licensee, is approved worldwide for the treatment of a form of wet age-related macular degeneration, the leading cause of legal blindness in people over the age of 55 in North America and Europe.
License Property
Under the Amended PDT Agreement, the Licensor will have exclusive U.S. sales and marketing rights to Visudyne, including rights to all end-user revenue derived from Visudyne sales in the U.S. The Licensee will have marketing and sales rights in all countries outside of the U.S. until the expiry of the Amended PDT Agreement on December 31, 2019.  The Licensor will continue to manufacture Visudyne and will supply the product at a pre-specified price exclusively to the Licensee for ex-US distribution.  The Parties will each be responsible for all costs and expenses associated with marketing and sales in their respective territories.  Also under the Amended PDT Agreement, the Parties have released each other from all open claims the parties may have against each other, including any in connection with any litigation with Massachusetts Eye and Ear Infirmary and any litigation with General Hospital Corporation (doing business as Massachusetts General Hospital).

IPSCIO Record ID: 202848

License Grant
In the original, the parties agreed to cooperate in the development, manufacturing and distribution of photosensitizers in photodynamic therapy for the treatment, diagnosis and prevention of ophthalmologic conditions.  The first amendment was to co-develop Verteporfin for use in photodynamic therapy in connection with the treatment, diagnosis or prevention of dermatological tumours, and other pathological conditions of the skin in which the primary cause is attributable to vascular abnormalities but excluding psoriasis, and excluding the use of Verteporfin in PDV, on the terms and conditions set out therein.  The second amendment was a right of first option to negotiate to participate in the commercialization of Verteporfin in PDT in dermatological conditions other than dermatological tumors.

This amended and restated agreement is to modify certain terms of the Agreement, and to license to Licensor all rights to continue to develop, and commercialize Verteporfin in the United States.

The Canadian Licensor grants to the Swiss Licensee and its Affiliates an exclusive, even to Licensor, perpetual license under the Licensor Technology, to research, develop, use, import, offer for sale and sell the Visudyne Product in the Field in the Licensees Territory. This license shall include the right to grant sublicenses through multiple tiers of sublicensees. Additionally, effective as of the Transition Effective Date, and subject to the terms and conditions of this Agreement, Licensor grants to Licensee and its Affiliates a non-exclusive, perpetual license under the Licensors Technology, to make and have made the Visudyne Product anywhere in the world solely for the purpose of exercising its rights under this Agreement, subject to Licensor’s right to be the sole supplier of the Visudyne Product.

Licensor grants to Licensee and its Affiliates a non-exclusive, perpetual license under the Licensors Patents to research, develop, use, import, offer for sale and sell the Visudyne Product in the Field in the Licensees Territory.  Additionally, effective as of the Transition Effective Date, and subject to the terms and conditions of this Agreement, Licensor grants a non-exclusive, perpetual license under the Patents, to make and have made the Visudyne Product anywhere in the world solely for the purpose of exercising its rights under this Agreement, subject to QLT’s right to be the sole supplier of the Visudyne Product. These licenses shall include the right to grant sublicenses through multiple tiers of sublicensees.

License Property
PDT means the field of photodynamic therapy, that is, the emerging medical field that uses photosensitive compounds and light in the diagnosis, treatment or prevention of human diseases.

The Product means (prior to the Transition Effective Date) BPD; ZnPc; and/or any additional Photosensitizer.

Patents relate to, but are not limited to, Wavelength-Specific Cytotoxic Agent; Derivatives for Photodynamic Therapy;  and Liposome Compositions.

Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.  Visudyne is a light-activated drug used in photodynamic therapy for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.

Field of Use
The Field means any usage of PDT for the treatment, diagnosis or prevention of ophthalmologic conditions, including but not limited to, age-related macular degeneration (AMD), diabetic retinopathy, corneal neovascularization, ocular tumours and epithelial overgrowth following cataract surgery (secondary cataracts).

IPSCIO Record ID: 344589

License Grant
Licensor grants an exclusive, worldwide license and sublicense, with the right to sublicense, under the Licensor Technology, based on existing agreements in place, to research, develop, use, have used, make, have made, import or have imported, export or have exported, offer for sale or have offered for sale, and/or sell or have sold Licensed Products in the Field.
License Property
The various patents relate to Treating Ocular Disorders and include but are not limited to
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved · for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
Field of Use
Licensee has the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.

Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.

IPSCIO Record ID: 3459

License Grant
In February of 2006, the Company acquired all of the outstanding stock of Ocular Therapeutics Inc. (OTI). OTI holds a license to certain patented technology relating to a small protein therapeutic (LD22-4) for the treatment of the wet form of age related macular degeneration. Because LD22-4 directly targets a fundamental requirement for the proliferation of blood vessels, i.e. cell migration, the Company believes that its mode of action is distinct from other drugs that are on the market or that are in development by other biotechnology or pharmaceutical companies.
Field of Use
The Company is a medical device company focused on the marketing and development of ophthalmic surgery products for use in the laser eye surgery and cataract surgery markets.

IPSCIO Record ID: 3199

License Grant
The Licensor entered into a License and collaboration Agreement with Licensee for the global development and commercialization outside the United States of EYLEA® (aflibercept) Injection.

Pursuant to the Amendment, the Licensor consented to the commercialization of EYLEA in Japan pursuant to a Co-Promotion and Distribution Agreement, which was executed concurrently with the execution of the Amendment.

License Property
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with neovascular (Wet) Age-related Macular Degeneration (AMD).

IPSCIO Record ID: 369411

License Grant
Canadian University hereby grants to the Canadian Licensee an exclusive, worldwide license to use and sublicense the Technology, all UBC Improvements and to manufacture, distribute, and sell Products on the terms and conditions hereinafter set forth during the term of this Agreement.
License Property
U.S. Patents
5,283,255 – Wavelength-specific cytotoxic agents
5,756,540 – Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
5,399,583 – Method of treating skin diseases

Product(s) means goods manufactured using the Technology or Improvements, including Visudyne.

Visudyne bverteporfin therapy for the treatment of age-related macular degeneration and other conditions developed and manufactured by practicing one or more of the Valid Patent Claims Las outlined in Agreement) which fall within the definition of the Technology.

UBC Improvements Any and all improvements, variations, updates, modifications, enhancements and alterations related to the Technology, including all improvements, variations, updates, modifications, enhancements and alterations relating to photodynamic compounds or therapies, which are conceived, invented, developed and/or acquired solely by UBC Personnel, or by UBC Personnel jointly with the Licensee at any time after the Commencement Date, whether patentable or not,
(i) if patentable, claim priority from any of the patents or patent applications which comprise the Technology and can not be used or practiced without a licence of Technology,
(ii) if not patentable, which relate directly to the Technology, or
(iii) inventions or developments by Dr. Dolphin relating to photodynamic therapy.

Field of Use
Licensee's commercial product, Visudyne, utilizes PDT to treat the eye disease known as wet age related macular degeneration, or “wet AMD,” the leading cause of blindness in people over the age of 55 in North America and Europe.
Photodynamic therapy or “PDT” uses photosensitizers (light activated drugs) in the treatment of disease.

Field of use is for the treatment of age-related macular degeneration and other conditions.

IPSCIO Record ID: 2709

License Grant
The Licensee entered into an exclusive License Agreement with two individuals pursuant to which the Licensee Licensed the rights for the manufacture, distribution and marketing of products based on Z-monocys – zinc-based moiety, zinc-monocysteine.  -monocys is initially being developed as an oral treatment for dry age-related macular degeneration (AMD).
License Property
Z-monocys is a patented composition of matter protected by U.S. patent 6,586,611, issued Jul. 1, 2003, and U.S. patent 7,164,035, issued Jan. 16, 2007.  Macular degeneration is a progressive eye condition affecting approximately 10 million Americans. AMD is associated with tissue deterioration in the center of vision, the macula of the retina, where the sharpest vision occurs in the eye.

Zinc, an essential nutrient, is the second most abundant trace element in the human body and the most abundant trace element in the eye. It is necessary for the activity of more than 200 enzymes and for the DNA binding capacity of over 400 nuclear regulatory elements. There is evidence that zinc may function as an antioxidant by protecting sulfhydryl groups from oxidation, competing with copper and iron to reduce the formation of hydroxyl radicals which are a result of redox cycling and by the induction of the antioxidant protein metallothionein (MT) which can scavenge damaging hydroxyls.

Field of Use
Field of Use shall mean all human and animal uses.

IPSCIO Record ID: 26094

License Grant
The Licensor hereby granted to the Licensee a royalty-bearing, exclusive worldwide right and license, with the right to grant sublicenses, for Cytokine Modulator (CM) as a therapeutic drug containing a single active pharmaceutical ingredient or two or more active pharmaceutical ingredients where no component of the CM is tacrolimus, cyclosporine, ISAtx24, Rapamycin (Sirolimus), Pimecrolimus, Everolimus, another calcineurin inhibitor or a corticosteroid. Subject to the terms and conditions of this Agreement, the Licensor shall grant the Licensee a right of reference to the Licensor Generated Data to Exploit Licensed Products in the Licensed Combination Field.
License Property
BOE Disease means the following diseases Wet Age-related Macular Degeneration; Dry Age-related Macular Degeneration; Posterior uveitis (chorioentinitis); Retinitis Pigmentosa; Retinal Vein Occlusion; Retinal detachment; Retinal Artery Occlusion; Proliferative diabetic retinopathy; Post-operative inflammation; Persistant Macular Edema; Neovascular diseases involving the retina or uveal tract such as neovascular glaucoma, neovascularization following a combined vitrectomy and lensectomy, neovascularization of the optic nerve, and neovascularization due to penetration of the eye or contusive ocular injury; Inflammation due to ocular trauma; Open-angle glaucoma; Closed-angle glaucoma; Exudative macular edema; Diabetic Retinopathy; Diabetic Macular Edema; Cystoid macular edema; Chronic posterior uveitis; Allograft rejection; Behcet's syndrome; Chorioiditis; Crystalline retinopathy; Optic neurtitis; Proliferative sickle cell retinopathy; Proliferative vitreoretinopathy; Retinopathy of prematurity; Vitreitis; Temporal arteritis; Fuchs' Dystrophy; Dacryocystitis; Giant cell arteritis; Sympathetic ophthalmia; Pars planitis; Pan Uveitis; and all other similar diseases as agreed to by the Parties.
Field of Use
Licensee has certain proprietary in vitro and in vivo models of ophthalmic diseases, and clinical expertise in developing ophthalmic therapeutics.  Collaboration Combination Field means use of a Collaboration Combination by Local Administration to treat the diseases.

IPSCIO Record ID: 5406

License Grant
During 2001, the Company entered into agreements with two biotechnology companies which are developing neutraceutical neuroprotective therapies for treating neurodegenerative disease such as macular degeneration and Parkinson’s disease. The CEO/director is affiliated with these companies.

IPSCIO Record ID: 3092

License Grant
The Licensor granted the Licensee an exclusive worldwide License to develop and commercialize diagnostic and pharmaceutical products based on compounds that inhibit the Licensor's proprietary target gene RTP801 through RNA interference.
License Property
The lead product candidate under the Agreement is the Company's drug candidate PF-655 (called in the past RTP801i-14) for treating ophthalmic diseases and potentially non-ophthalmic diseases, is currently in Phase II clinical trials for wet AMD and DME.

In March 2011, the Licensor amended its License Agreement with the Licensee.  Under the amendment, the Licensor will conduct at its own expense a Phase IIb trial of PF-655 in diabetic macular edema, under a protocol mutually agreed by both Parties.  Under the amendment, the Licensor will deliver the trial data to the Licensee upon completion.  After its review of the data, the Licensee will either make a milestone payment to the Licensor in an amount which exceeds the anticipated cost of the trial and resume responsibility for continued development of PF-655 at the Licensee's expense, or will terminate its license and return to the Licensor the rights to the product. In further consideration of the Licensor's conducting the Phase IIb trial, the Licensee agreed to increase the overall development and product approval milestone payments associated with the first ophthalmic use of PF-655 and to increase the royalty rates under the agreement. The Licensor may terminate the Phase IIb clinical trial if an independent monitoring committee determines futility at interim review points set forth in the protocol.

Field of Use
PF-655 is for the treatment of wet Age-related Macular Degeneration (wet AMD)2 (hereinafter “wet AMD”) and Diabetic Macular Edema (DME)3 (hereinafter “DME”).

IPSCIO Record ID: 249885

License Grant
The Parties announced a new collaboration to develop IONIS-FB-LRx for the treatment of complement-mediated diseases. This collaboration will leverage the companys leadership in RNA-targeted therapeutics to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases. The first indication the two companies will pursue is the treatment of patients with Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD). A Phase 2 study in patients with GA is planned to begin in early 2019.
License Property
IONIS-FB-LRx, an antisense drug using the companys advanced LIgand Conjugated Antisense (LICA) technology, reduces the production of FB, a key protein in the complement innate immune system. FB is predominately produced in the liver and circulates throughout the vascular system, including vessels in the eye and kidney. This complement protein plays a pivotal role in an innate immunogenic cascade that, when overactivated, has been associated with the development of several complement-mediated diseases, including dry AMD.

AMD means Age-related macular degeneration.

Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.